Danaher to Acquire Cepheid for $4 Billion in Major Molecular Diagnostics Move
On September 6, life sciences giant Danaher announced that it would acquire Cepheid, a U.S. supplier of molecular diagnostic products, for $4 billion. This acquisition has drawn particular attention because CepheidWith a market capitalization of only around $2.5 billion,The acquisition premium reached as high as 53%! This marks another major acquisition by Danaher, following its $13.8 billion purchase of Pall in 2015.
Cepheid, founded in 1996 and listed on the NASDAQ on June 30, 2000, is a provider of innovative molecular diagnostic products,Applying microfluidics and microelectronics to DNA analysis and amplification systems, integrating portable instruments with laboratory systems, to develop a DNA analysis system capable of rapidly and accurately detecting infectious pathogens, human genes, and environmental pollutants in industrial settings.Offers solutions covering the detection of a wide range of infectious diseases and tumors.
Danaher, founded in 1984, is one of the leading manufacturers in the United States and a rapidly growing Fortune 500 company with annual sales exceeding $8 billion. It employs 37,000 people worldwide. The company holds a leading position in the fields of professional instruments, industrial technologies, and tools and components, and maintains long-term investments in well-known and active international industrial enterprises.
Cepheid’s core competency is a molecular diagnostic sample preparation device known as “sample in, answer out.”This device is compatible with a wide variety of sample types, including blood, tissue, urine, and cerebrospinal fluid. It significantly streamlines the sample preparation process in molecular diagnostics, saving time. When used in conjunction with Cepheid’s diagnostic platforms, this sample processing device substantially enhances testing efficiency.
Currently, the global installed base of its diagnostic equipment, GeneXpert, has exceeded 10,000 units. According to statistics from Market Dx International, Cepheid holds the largest share of installed diagnostic equipment in U.S. hospitals, approaching 25%, surpassing even Roche, BD, and BioMérieux.
The GeneXpert system can perform 1–8 tests per run, and its flexible throughput appeals to a wide range of customers, including low-throughput point-of-care settings and high-throughput reference laboratories. In the United States, the GeneXpert catalog offers 20 assays, while 23 assays are available outside the United States.
From 2006 to 2015, Cepheid’s sales grew at a compound annual growth rate (CAGR) of 42%, reaching $540 million in 2015. Of this, clinical diagnostics accounted for $510 million, with diagnostic consumables comprising 84% of the total.
Based on current market penetration rates, Cepheid’s future business growth potential remains substantial, with POCT and oncology testing solutions likely to become the primary growth drivers.
“By leveraging the Danaher Business System and combining Cepheid with our existing position in the diagnostics industry, we believe Cepheid will be well positioned to improve operational efficiency, significantly expand profit margins, and drive Danaher’s long-term growth.””said Danaher CEO Thomas Joyce. The acquisition was unanimously approved by the boards of directors of both companies.
Post-Acquisition,Cepheid will be includedDanaher’s diagnostics segment, which already encompasses Beckman Coulter, Leica, and Radiometer, generates nearly $5 billion in annual sales, making it the largest division among all of the company’s business groups.
The acquisition of Cepheid, which generates $500 million in annual sales, will further strengthen the strategic position of diagnostics within Danaher’s business and enhance its competitiveness in the field of molecular diagnostics. Following this move, Danaher’s market capitalization will exceed $60 billion (based on its current organizational structure).
What is more interesting is that,Danaher and another giant, Thermo Fisher, have launched a frenzied M&A race.In 2013, Thermo Fisher acquired Life Technologies for $13.6 billion. In 2015, Danaher acquired Pall for $13.8 billion. ByIn early 2016, Thermo Fisher acquired Affymetrix for $4 billion. In August 2016, Danaher announced its acquisition of Cepheid for $4 billion. Following such industry reshuffling and mergers and acquisitions, these two companies will emerge as dominant players in the field, inevitably intensifying future competition.